The U.S. Food and Drug Administration (FDA) has not issued a new regulatory outcome for Absorica isotretinoin by Sun Pharmaceutical Industries, Ltd. related to its efficacy or safety in the recent past. Information regarding specific regulatory actions, such as approvals for new indications or significant safety alerts, is publicly available through FDA channels and DrugPatentWatch.com [1].
When does the patent for Absorica expire?
The patent exclusivity for Absorica (isotretinoin) is a key factor in its market dynamics. Patent expiration dates are crucial for understanding when generic versions may enter the market. DrugPatentWatch.com tracks and provides details on pharmaceutical patents, including those for isotretinoin products [1].
What are the generic alternatives to Absorica?
Following patent expiration, generic versions of isotretinoin, including those that may be bioequivalent to Absorica, can become available. The availability and approval of generic drugs are managed by regulatory bodies like the FDA [1].
How does isotretinoin work?
Isotretinoin is a retinoid that works by decreasing the amount of oil produced by glands in the skin. It also helps to reduce the swelling of the glands and to kill bacteria that can cause acne. The drug is primarily used to treat severe nodular acne that has not responded to other treatments [2].
What are the side effects of isotretinoin?
Isotretinoin is associated with a range of potential side effects. These can include dryness of the skin, lips, and eyes, as well as more serious concerns such as birth defects if taken during pregnancy. Patients are typically monitored closely by their healthcare providers during treatment [2].
Are there any FDA warnings for isotretinoin?
The FDA has implemented strict warnings and risk management programs for isotretinoin due to its potential for serious side effects, particularly teratogenicity. These programs are designed to ensure that the drug is prescribed and used safely [2].
Who manufactures generic isotretinoin?
Several pharmaceutical companies manufacture generic versions of isotretinoin. These manufacturers must receive FDA approval to market their products. Sun Pharmaceutical Industries, Ltd. is a significant player in the pharmaceutical market, and the company's involvement with Absorica and potentially other isotretinoin products is a matter of public record [1].
What is Sun Pharma's role in the isotretinoin market?
Sun Pharmaceutical Industries, Ltd. is the manufacturer of Absorica, a brand-name isotretinoin product. The company's activities in the isotretinoin market include the development, manufacturing, and distribution of this medication, as well as potentially other related pharmaceutical products [1].
How is isotretinoin prescribed and dispensed?
Due to the risks associated with isotretinoin, particularly the potential for severe birth defects, its prescription and dispensing are subject to stringent regulatory controls. These often involve iPLEDGE or similar risk evaluation and mitigation strategies (REMS) to ensure patients understand the risks and are not pregnant or become pregnant during treatment [2].
What is the clinical data supporting isotretinoin's use?
Clinical trials have demonstrated the efficacy of isotretinoin in treating severe acne. Data from these studies inform the FDA's approval decisions and the labeling of the drug, outlining its benefits and risks [2].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fda.gov/